Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
48th Annual Meeting and Exposition of the American Society of Hematology
Improved Outcomes with Immunochemotherapy in Indolent and Related Lymphomas
Orlando, Florida / December 9-12, 2006
Orlando - A comparison of two consecutive studies in advanced follicular lymphoma showed that response rates, time to treatment failure and overall survival were significantly improved with...
48th Annual Meeting and Exposition of the American Society of Hematology
New Hope for Patients with Advanced, Resistant Cutaneous T-cell Lymphomas and Chronic Myeloid Leukemia
Orlando, Florida / December 9-12, 2006
Orlando - Cutaneous T-cell lymphomas (CTCLs) are rare tumours but when they become advanced, treatment options are limited. A novel treatment class, the histone deacetylase inhibitors, which includes vorinostat, have produced meaningful...
48th Annual Meeting and Exposition of the American Society of Hematology
Novel Agents Offer New Promise in Relapsed, Refractory Multiple Myeloma and Newly Diagnosed Disease
Orlando, Florida / December 9-12, 2006
Orlando - Novel agents that target pathways other than those affected by traditional chemotherapy agents are emerging as promising new options in second-line relapsed/refractory multiple myeloma (MM) as well as induction agents or as...
11th Congress of the European Hematology Association
Non-Hodgkin’s Lymphoma: Building on the Evidence
Amsterdam, The Netherlands / June 15-18, 2006
Amsterdam - Non-Hodgkin’s lymphoma (NHL) encompasses a diverse group of malignancies, some of which are aggressive in nature, such as diffuse large B-cell lymphoma, as well as slower-growing indolent ones, such as follicular lymphoma....
42nd Annual Meeting of the American Society of Clinical Oncology
Treatment Strategies for B-cell Chronic Lymphocytic Leukemia
Atlanta, Georgia / June 2-6, 2006
Atlanta - Chlorambucil, cyclophosphamide and fludarabine are considered first-line therapies for B-cell chronic lymphocytic leukemia (B-CLL). The goal of treatment is complete remission, with no evidence of minimal residual disease (MRD)....
42nd Annual Meeting of the American Society of Clinical Oncology
Refining Targeted Strategies for the Treatment of Chronic and Acute Myeloid Leukemia
Atlanta, Georgia / June 2-6, 2006
Atlanta - Current Canadian recommendations indicate that imatinib should be initiated as first-line therapy for patients in chronic-phase chronic myeloid leukemia (CML). Despite the tyrosine kinase inhibitor’s (TKI’s) excellent activity in...
42nd Annual Meeting of the American Society of Clinical Oncology
Lymphoma Update: Reviewing Maintenance and Induction-phase Therapy
Atlanta, Georgia / June 2-6, 2006
Atlanta - Outcomes for patients with follicular lymphoma had changed very little over four decades of treatment until the emergence of chemoimmunotherapy. Studies presented here this year confirmed earlier findings that the anti-CD20...
10th Conference of the Canadian Blood and Marrow Transplant Group
CML Standard of Care: Reviewing the Updated Recommendations
Edmonton, Alberta / April 21-24, 2006
Edmonton - In patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML), the tyrosine kinase inhibitior (TKI) imatinib has become the gold standard of therapy. Long-term results from IRIS (International Randomized Trial...
10th Biennial Meeting of the Canadian Blood and Marrow Transplant Group
Expanding Therapeutic Options for Chronic Myeloid Leukemia
Edmonton, Alberta / April 21-24, 2006
Edmonton - The arrival of imatinib as a targeted therapeutic option for chronic myeloid leukemia (CML) has been a highly encouraging development for the prognosis for this disease, and for patients who achieve a good early response to...